Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex ...

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain treatment that could be a game-changer for both patients and the company ...

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

Vertex Pharmaceuticals (VRTX) reachead $475.49 at the closing of the latest trading day, reflecting a -1.41% change compared to its last close.

As the U.S. stock market navigates a period of heightened volatility, with major indexes experiencing significant fluctuations amid tariff discussions and economic uncertainties, investors are keenly ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other best long term growth stocks to buy according to billionaires.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

BOSTON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets ...

BOSTON, April 11, 2025--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Paul Negulescu, Ph.D. Senior Vice President, Vertex has been awarded the 2025 Canada Gairdner ...